Recent Share Performance and Business Snapshot

Addus HomeCare (ADUS) has drawn fresh attention after recent trading, with the stock last closing at $96.86. Investors are weighing this price move against the company’s latest financial figures and return profile.

Over the past week, the stock gained 2.79%, with an increase of 3.95% over the past month and 1.75% over the past 3 months. Year to date, the share price is down 9.12%, and the 1 year total return has declined 16.24%.

Over a longer horizon, Addus HomeCare’s total return is 3.78% over 3 years and 8.83% over 5 years. These mixed results may lead readers to compare shorter term trading swings with the company’s multi year performance.

The company reports annual revenue of US$1.45b and net income of US$99.75m. Based on the data provided, annual revenue growth is 4.93% and net income growth is 11.11%, which some investors may use to assess current pricing.

Addus HomeCare operates through three segments: Personal Care, Hospice, and Home Health. Personal Care is the largest contributor, generating US$1,112.02m in revenue, followed by Hospice at US$266.89m and Home Health at US$69.52m.

All reported revenue currently comes from the United States, where the company provides in home services for elderly, chronically ill, disabled, and other high risk individuals. Its clients include government agencies, managed care organizations, commercial insurers, and private pay customers.

The recent 1 month share price return of 3.95% has partially offset the year to date share price decline of 9.12%. The 1 year total shareholder return is down 16.24%, so recent momentum for Addus HomeCare appears to be rebuilding from a weaker longer term base.

If you are weighing Addus HomeCare against other opportunities in the sector, this could be a good moment to scan for peers using our healthcare focused screener to see which businesses stand out as potential candidates, including those in 39 healthcare AI stocks.

With Addus HomeCare trading at $96.86 alongside valuation estimates that imply a discount to some intrinsic and analyst targets, the key question is whether the stock is still undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 4% Undervalued

At a last close of $96.86 versus a narrative fair value of $100.85, Addus HomeCare is framed as modestly undervalued, with that gap hinging on specific growth and margin assumptions.

The looming threat of significant government healthcare spending cuts to address federal budget deficits could reduce funding for Medicaid and Medicare programs, which are critical revenue streams for Addus HomeCare, this would directly pressure revenue and earnings, especially as provisions of the reconciliation bill begin to impact state budgets in 2028.

Read the complete narrative. Read the complete narrative.

The narrative leans on steady revenue expansion, firmer profit margins, and a higher future earnings base, all run through a 7.11% discount rate and a tighter share count outlook. It is this combination, rather than any single aggressive bet, that underpins the $100.85 fair value against today’s $96.86 price.

Result: Fair Value of $100.85 (UNDERVALUED)

However, Addus HomeCare could still surprise this narrative if reimbursement rate gains in key states and contributions from recent acquisitions prove more resilient than expected.

Next Steps

If this mix of risks and potential rewards around Addus HomeCare feels finely balanced, it may be worth acting soon to review the underlying drivers yourself and see what investors are optimistic about in the company’s 5 key rewards

Looking for more Addus HomeCare sized investment ideas?

If Addus HomeCare has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to spot other opportunities that could fit your approach.

• Target potential value opportunities by scanning companies with stronger fundamentals than their prices suggest through the 43 high quality undervalued stocks.
• Prioritise resilience by reviewing companies that show robust finances and staying power using the 67 resilient stocks with low risk scores.
• Spot potential early stage winners by checking a 22 elite penny stocks with strong financials that already show healthier financial profiles than many peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.